ECM
BBIO icon

ExodusPoint Capital Management’s BridgeBio Pharma BBIO Stock Holding History

ExodusPoint Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-125,302
Closed -$9.58M – 1563
2025
Q4 		$9.58M Buy
125,302
+94,874
+312% +$6.23M 0.08% 268
2025
Q3 		$1.58M Sell
30,428
-160,139
-84% -$7.81M 0.02% 807
2025
Q2 		$8.23M Buy
190,567
+155,188
+439% +$5.64M 0.07% 285
2025
Q1 		$1.22M Buy
+35,379
New +$1.19M 0.01% 866
2024
Q3 		– Sell
-14,890
Closed -$377K – 1623
2024
Q2 		$377K Buy
+14,890
New +$407K ﹤0.01% 1274
2023
Q2 		– Sell
-12,624
Closed -$209K – 1851
2023
Q1 		$209K Buy
+12,624
New +$147K ﹤0.01% 1566
2022
Q4 		– Sell
-162,981
Closed -$1.62M – 1641
2022
Q3 		$1.62M Sell
162,981
-73,131
-31% -$760K 0.02% 898
2022
Q2 		$2.14M Buy
236,112
+143,854
+156% +$1.2M 0.03% 756
2022
Q1 		$936K Buy
+92,258
New +$947K 0.01% 1201
2021
Q4 		– Sell
-26,393
Closed -$1.24M – 2167
2021
Q3 		$1.24M Buy
+26,393
New +$1.41M 0.02% 933
2021
Q2 		– Sell
-10,889
Closed -$671K – 2340
2021
Q1 		$671K Buy
+10,889
New +$712K 0.01% 1158

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's BBIO Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 125,302 shares — an estimated $9.58M sold.

ExodusPoint Capital Management first reported a position in BBIO in Q1 2021 and held it in 11 quarters. The position peaked at $9.58M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 125,302 BridgeBio Pharma shares in Q1 2026, an estimated $9.58M.
  • ExodusPoint Capital Management first reported a position in BridgeBio Pharma in Q1 2021 and held it in 11 quarters.
  • ExodusPoint Capital Management's BridgeBio Pharma position peaked at $9.58M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.